2-methyl-phthalazinium | 63858-86-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 2-methyl-phthalazinium
• 英文别名: 2-methyl-phthalazinium cation；mono-N-Methyl-phthalazinium⁺；N-Methyl-phthalazinium；2-Methyl-phthalzinium；2-Methylphthalazinium；2-Methylphthalazin-2-ium
• CAS: 63858-86-6
• 化学式: C₉H₉N₂
• 分子量: 145.184
• InChiKey: NHOFIFLKIXMRJA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  16.8
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-苯甲基-1,4-二氢烟酰胺 、 2-methyl-phthalazinium 以 水 、 乙腈 为溶剂， 生成 2-甲基-1,2-二氢二氮杂萘 、 1-benzyl-3-carbamoylpyridinium ion
  参考文献：
  名称：

  Kinetics of the reduction of isoquinolinium cations by 1,4-dihydronicotinamides

  摘要：

  DOI：

  10.1021/jo00133a014

文献信息

• Methods and compositions for treating cardiovascular disease using 1722, 10280, 59917, 85553, 10653, 9235, 21668, 17794, 2210, 6169, 10102, 21061, 17662, 1468, 12282, 6350, 9035, 1820, 23652, 7301, 8925, 8701, 3533, 9462, 9123, 12788, 17729, 65552, 1261, 21476, 33770, 9380, 2569654, 33556, 53656, 44143, 32612, 10671, 261, 44570, 41922, 2552, 2417, 19319, 43969, 8921, 8993, 955, 32345, 966, 1920, 17318, 1510, 14180, 26005, 554, 16408, 42028, 112091, 13886, 13942, 1673, 54946 or 2419
  申请人：Stagliano E. Nancy

  公开号：US20050037946A1

  公开（公告）日：2005-02-17

  The present invention relates to methods for the diagnosis and treatment of cardiovascular disease, including, but not limited to, atherosclerosis, reperfusion injury, hypertension, restenosis, arterial inflammation, thrombosis and endothelial cell disorders. Specifically, the present invention identifies the differential expression of 1722, 10280, 59917, 85553, 10653, 9235, 21668, 17794, 2210, 6169, 10102, 21061, 17662, 1468, 12282, 6350, 9035, 1820, 23652, 7301, 8925, 8701, 3533, 9462, 9123, 12788, 17729, 65552, 1261, 21476, 33770, 9380, 2569654, 33556, 53656, 44143, 32612, 10671, 261, 44570, 41922, 2552, 2417, 19319, 43969, 8921, 8993, 955, 32345, 966, 1920, 17318, 1510, 14180, 26005, 554, 16408, 42028, 112091, 13886, 13942, 1673, 54946 and 2419 genes in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. The present invention describes methods for the diagnostic evaluation and prognosis of various cardiovascular diseases, and for the identification of subjects exhibiting a predisposition to such conditions. The invention also provides methods for identifying a compound capable of modulating cardiovascular disease. The present invention also provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease.

  本发明涉及心血管疾病的诊断和治疗方法，包括但不限于动脉粥样硬化、再灌注损伤、高血压、再狭窄、动脉炎症、血栓形成和内皮细胞疾病。具体地说，本发明鉴定了 1722、10280、59917、85553、10653、9235、21668、17794、2210、6169、10102、21061、17662、1468、12282, 6350, 9035, 1820, 23652, 7301, 8925, 8701, 3533, 9462, 9123, 12788, 17729, 65552, 1261, 21476, 33770, 9380, 2569654, 33556, 53656, 44143, 32612, 10671, 261, 44570,41922, 2552, 2417, 19319, 43969, 8921, 8993, 955, 32345, 966, 1920, 17318, 1510, 14180, 26005, 554, 16408, 42028, 112091, 13886, 13942, 1673, 54946 和 2419 基因在心血管疾病状态下的表达，相对于它们在正常或非心血管疾病状态下的表达，和/或对心血管疾病相关操作的反应。本发明描述了对各种心血管疾病进行诊断评估和预后判断的方法，以及对表现出此类疾病易感性的受试者进行鉴定的方法。本发明还提供了鉴定能够调节心血管疾病的化合物的方法。本发明还提供了用于鉴定和治疗心血管疾病的化合物的方法。
• EP1583966A4
  申请人：——

  公开号：EP1583966A4

  公开（公告）日：2007-06-27
• METHODS AND COMPOSITIONS FOR TREATING CARDIOVASCULAR DISEASE USING 1722, 10280, 59917, 85553, 10653, 9235, 21668, 17794, 2210, 6169, 10102, 21061,17662,1468,12282, 6350, 9035,1820, 23652, 7301, 8925, 8701, 3533, 9462, 9123,12788,17729, 65552,1261, 21476, 33770, 9380, 2569654, 33556, 53656, 44143, 32
  申请人：MILLENNIUM PHARMACEUTICALS, INC.

  公开号：EP1583966A2

  公开（公告）日：2005-10-12
• Cephem Compounds Having Broad Antibacterial Spectrum
  申请人：Nishitani Yasuhiro

  公开号：US20090131655A1

  公开（公告）日：2009-05-21

  A compound of the formula: (wherein, T is S, SO or O; X is halogen, CN, carbamoyl optionally substituted with lower alkyl, lower alkyl, lower alkoxy, or lower alkylthio; A is substituted lower alkylene (wherein the substituent is optionally substituted mono lower alkyl, optionally substituted lower alkylidene, or optionally substituted lower alkylene) Z + is an optionally substituted, a cation and an N atom-containing heterocyclic group), ester, amino-protected compound wherein the amino bonds to a thiazole ring at the 7-position, or pharmaceutically acceptable salt or solvate thereof.
• US6610730B2
  申请人：——

  公开号：US6610730B2

  公开（公告）日：2003-08-26